These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36285390)

  • 1. [Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer 
Based on Molecular Markers].
    Guangdong Association of Thoracic Diseases
    Zhongguo Fei Ai Za Zhi; 2022 Oct; 25(10):701-714. PubMed ID: 36285390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer.
    Shoji F; Morodomi Y; Akamine T; Takamori S; Katsura M; Takada K; Suzuki Y; Fujishita T; Okamoto T; Maehara Y
    Lung Cancer; 2016 Aug; 98():15-21. PubMed ID: 27393501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
    Lu Y; Wang L; Liu P; Yang P; You M
    PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation markers and early recurrence in stage I lung cancer.
    Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
    N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lung microbiome, peripheral gene expression, and recurrence-free survival after resection of stage II non-small cell lung cancer.
    Peters BA; Pass HI; Burk RD; Xue X; Goparaju C; Sollecito CC; Grassi E; Segal LN; Tsay JJ; Hayes RB; Ahn J
    Genome Med; 2022 Oct; 14(1):121. PubMed ID: 36303210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors of postoperative recurrences in patients with clinical stage I NSCLC.
    Chen YY; Huang TW; Tsai WC; Lin LF; Cheng JB; Chang H; Lee SC
    World J Surg Oncol; 2014 Jan; 12():10. PubMed ID: 24410748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Distant Recurrence in Patients With Resected Stage I Lung Cancer: A Case Series of "Blast Metastasis".
    Ekeke CN; Mitchell C; Schuchert M; Dhupar R; Luketich JD; Okusanya OT
    Clin Lung Cancer; 2021 Jan; 22(1):e132-e135. PubMed ID: 33144072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases.
    Benlloch S; Galbis-Caravajal JM; Alenda C; Peiró FM; Sanchez-Ronco M; Rodríguez-Paniagua JM; Baschwitz B; Rojas E; Massutí B
    Ann Oncol; 2009 Jan; 20(1):91-7. PubMed ID: 18664559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The prognostic impact of preoperative PET-CT on postoperative recurrence for completely resected stage I non-small cell lung cancer].
    Qiang G; Xu R; Liu J; Yan J; Xu Y; Di J; Da J; Liang C; Shi B; Guo Y; Liu D
    Zhonghua Wai Ke Za Zhi; 2015 Jul; 53(7):502-7. PubMed ID: 26359072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer.
    Kanaoka R; Iinuma H; Dejima H; Sakai T; Uehara H; Matsutani N; Kawamura M
    Oncology; 2018; 94(5):311-323. PubMed ID: 29533963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].
    Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):741-761. PubMed ID: 32957170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is 'cured' from postoperative recurrence?
    Sekihara K; Hishida T; Yoshida J; Oki T; Omori T; Katsumata S; Ueda T; Miyoshi T; Goto M; Nakasone S; Ichikawa T; Matsuzawa R; Aokage K; Goto K; Tsuboi M
    Eur J Cardiothorac Surg; 2017 Sep; 52(3):522-528. PubMed ID: 28482033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model.
    Mitra R; Lee J; Jo J; Milani M; McClintick JN; Edenberg HJ; Kesler KA; Rieger KM; Badve S; Cummings OW; Mohiuddin A; Thomas DG; Luo X; Juliar BE; Li L; Mesaros C; Blair IA; Srirangam A; Kratzke RA; McDonald CJ; Kim J; Potter DA
    Clin Cancer Res; 2011 May; 17(9):2934-46. PubMed ID: 21242119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study.
    Zhang Y; Zheng D; Xie J; Li Y; Wang Y; Li C; Xiang J; Zhang Y; Hu H; Sun Y; Chen H
    Chest; 2018 Sep; 154(3):501-511. PubMed ID: 29758181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
    Gupta AR; Woodard GA; Jablons DM; Mann MJ; Kratz JR
    Future Oncol; 2021 Dec; 17(34):4785-4795. PubMed ID: 34435876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer.
    Lou F; Sima CS; Rusch VW; Jones DR; Huang J
    Ann Thorac Surg; 2014 Nov; 98(5):1755-60; discussion 1760-1. PubMed ID: 25110337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and risk factors of recurrence in clinical stage I non-small cell lung cancer patients undergoing anatomic segmentectomy.
    Koike T; Nakamura A; Shimizu Y; Goto T; Sato S; Toyabe SI; Tsuchida M
    Gen Thorac Cardiovasc Surg; 2020 Sep; 68(9):1011-1017. PubMed ID: 32198710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer.
    Li W; Wang Y; Zhang Q; Tang L; Liu X; Dai Y; Xiao L; Huang S; Chen L; Guo Z; Lu J; Yuan K
    PLoS One; 2015; 10(8):e0134220. PubMed ID: 26237047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.